Imatinib Sandoz

Imatinib, the active ingredient in Imatinib Sandoz, is a tyrosine kinase inhibitor presented as an oral dosage form for oral use. It is used to treat certain blood cancers and solid tumors, notably chronic myeloid leukemia and gastrointestinal stromal tumor, in adult patients.

GNH USA supplies Imatinib Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑compliant documentation for global distribution.

Imatinib acts on malignant cells driven by specific tyrosine‑kinase pathways, providing targeted therapy for several oncologic conditions.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and induces remission. - Gastrointestinal stromal tumor (GIST): inhibits tumor growth by blocking KIT signaling. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to disease control in adult patients.

Imatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Edema: swelling of the hands, feet, or face. - Fatigue: persistent tiredness. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Neutropenia: marked reduction in white blood cells. - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiac failure: signs of reduced heart function.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor relevant laboratory parameters.

- Monitor blood counts: check complete blood count regularly. - Assess liver function: perform baseline and periodic liver enzyme tests. - Avoid strong CYP3A4 inhibitors: they may increase imatinib exposure. - Caution in cardiac disease: evaluate cardiac status before use. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture.

Imatinib interacts with several drug classes; careful review of concomitant medications is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower efficacy. - Antacids containing aluminum or magnesium: can reduce absorption. - Warfarin: may increase INR and bleeding risk.

Moderate Interactions (Monitor Closely): - QT‑prolonging agents (e.g., quinidine): monitor cardiac rhythm. - CYP2C8 substrates (e.g., paclitaxel): observe for altered plasma concentrations.